The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia.
AML
Akt
AraC
apoptosis
isoselenocyanate-4
primary human AML cells
xenograft
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
11
11
2019
accepted:
05
03
2020
entrez:
17
4
2020
pubmed:
17
4
2020
medline:
17
4
2020
Statut:
epublish
Résumé
Acute myeloid leukemia is a heterogeneous disease with a 5-year survival rate of 28.3%, and current treatment options constrained by dose-limiting toxicities. One of the key signaling pathways known to be frequently activated and dysregulated in AML is PI3K/AKT. Its dysregulation is associated with aggressive cell growth and drug resistance. We investigated the activity of Phenybutyl isoselenocyanate (ISC-4) in primary cells obtained from newly diagnosed AML patients, diverse AML cell lines, and normal cord blood cells. ISC-4 significantly inhibited survival and clonogenicity of primary human AML cells without affecting normal cells. We demonstrated that ISC-4-mediated p-Akt inhibition caused apoptosis in primary AML (CD34
Identifiants
pubmed: 32296637
doi: 10.3389/fonc.2020.00393
pmc: PMC7140985
doi:
Types de publication
Journal Article
Langues
eng
Pagination
393Subventions
Organisme : NCI NIH HHS
ID : P01 CA171983
Pays : United States
Informations de copyright
Copyright © 2020 Annageldiyev, Tan, Thakur, Dhanyamraju, Ramisetti, Bhadauria, Schick, Zeng, Sharma, Dunton, Dovat, Desai, Zheng, Feith, Loughran, Amin, Sharma, Claxton and Sharma.
Références
Front Oncol. 2017 Nov 06;7:263
pubmed: 29164062
Pharmacol Ther. 1998 Sep;79(3):179-92
pubmed: 9776375
Blood Cancer J. 2016 Jul 01;6(7):e441
pubmed: 27367478
Pharm Pat Anal. 2015;4(3):187-205
pubmed: 26030080
Nat Rev Cancer. 2002 Jan;2(1):48-58
pubmed: 11902585
J Control Release. 2010 Jan 25;141(2):137-44
pubmed: 19751777
Nature. 1994 Feb 17;367(6464):645-8
pubmed: 7509044
Cell. 2017 Apr 20;169(3):381-405
pubmed: 28431241
Mol Cell Proteomics. 2009 Mar;8(3):443-50
pubmed: 18952599
Drug Metab Dispos. 1999 Jan;27(1):13-20
pubmed: 9884304
PLoS One. 2013;8(3):e59380
pubmed: 23555026
Hum Mol Genet. 2006 Jun 1;15(11):1894-913
pubmed: 16644866
Clin Epigenetics. 2018 Jun 19;10:83
pubmed: 29951132
J Cell Biochem Suppl. 1997;27:76-85
pubmed: 9591196
Haematologica. 2020 Mar;105(3):687-696
pubmed: 31123028
Cancer Prev Res (Phila). 2011 Feb;4(2):248-58
pubmed: 21097713
Signal Transduct Target Ther. 2019 Jun 19;4:20
pubmed: 31240133
N Engl J Med. 2006 Sep 21;355(12):1253-61
pubmed: 16990388
Leukemia. 2003 May;17(5):995-7
pubmed: 12750723
Lab Invest. 2006 Dec;86(12):1203-7
pubmed: 17075578
Am J Hematol. 2017 Jan;92(1):7-11
pubmed: 27673440
Clin Cancer Res. 2009 Mar 1;15(5):1674-85
pubmed: 19208796
Blood. 2016 Sep 29;128(13):1671-8
pubmed: 27421961
PLoS One. 2015 Oct 05;10(10):e0139657
pubmed: 26436418
Nat Med. 1997 Jul;3(7):730-7
pubmed: 9212098
Expert Opin Investig Drugs. 2009 Sep;18(9):1333-49
pubmed: 19678801
Carcinogenesis. 1992 Jul;13(7):1167-70
pubmed: 1638682
Nat Med. 2017 Feb;23(2):250-255
pubmed: 27991919
Molecules. 2016 Nov 11;21(11):
pubmed: 27845732
Oncotarget. 2017 Jun 6;8(23):38022-38043
pubmed: 28410237
Blood. 2008 Dec 15;112(13):4793-807
pubmed: 19064739
Proc Natl Acad Sci U S A. 2007 Jun 26;104(26):11008-13
pubmed: 17576927
BBA Clin. 2015 Jul 23;4:59-68
pubmed: 26674329
Trends Cell Biol. 2005 Sep;15(9):494-501
pubmed: 16084092
Blood. 2017 Mar 23;129(12):1627-1635
pubmed: 28159738
Blood. 2012 Jan 26;119(4):911-23
pubmed: 22065598
Blood. 2010 Feb 18;115(7):1406-15
pubmed: 20008787
Cell Stem Cell. 2009 Jul 2;5(1):31-42
pubmed: 19570512
Carcinogenesis. 1989 Sep;10(9):1757-9
pubmed: 2766468
J Clin Med. 2016 Mar 05;5(3):
pubmed: 26959069
Oncogene. 2016 Sep 29;35(39):5119-31
pubmed: 26999641
Clin Cancer Res. 2011 Jul 1;17(13):4474-83
pubmed: 21555373
Cancer Res. 1994 Aug 15;54(16):4327-33
pubmed: 8044780
N Engl J Med. 2016 Jun 9;374(23):2209-2221
pubmed: 27276561
Leukemia. 2020 Jan;34(1):50-62
pubmed: 31201358
N Engl J Med. 2015 Sep 17;373(12):1136-52
pubmed: 26376137
Cell Stem Cell. 2015 Oct 1;17(4):412-21
pubmed: 26387756
Biomark Res. 2014 Feb 10;2(1):4
pubmed: 24513123
Nature. 2001 Nov 1;414(6859):105-11
pubmed: 11689955
N Engl J Med. 1989 Oct 26;321(17):1174-8
pubmed: 2571931
Anticancer Agents Med Chem. 2009 Jun;9(5):550-9
pubmed: 19519296
J Hematol Oncol. 2019 Apr 24;12(1):40
pubmed: 31014364
Br J Cancer. 2015 Jun 9;112(12):1976-7
pubmed: 25584491
Mol Cancer. 2017 Jan 30;16(1):2
pubmed: 28137304
J Med Chem. 2008 Dec 25;51(24):7820-6
pubmed: 19053750
Nat Methods. 2014 Apr;11(4):436-42
pubmed: 24562423
Sci Rep. 2017 Feb 08;7:41950
pubmed: 28176818
Cell Stem Cell. 2010 Dec 3;7(6):708-17
pubmed: 21112565